ACTRN12621000845831招募中未知
Kia Timata Pai (Best Start): A cluster randomised trial with early childhood teachers to support children's oral language and self-regulation development
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 5,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Educational / counselling / training
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 13 Months 至 75 Years（—）
- 性别
- All
入选标准
- •There will be no gender, racial/ethnic, language, or socioeconomic restrictions to
- •participation in this study. All children within the target age group (from 13 to 30 months at enrolment) will be exposed to the interventions within their early childhood education centre (ECEC). We are collaborating with a large national early childhood education (ECE) organisation called BestStart within which all 1,600 planned child participants, their parents, and 300 planned ECE teachers will be recruited, but data will not be collected on those children whose families have not granted consent.
排除标准
- •Children with a pervasive developmental disorder or history of
- •brain trauma will be excluded from data analyses due to our focus on neurodevelopment outcomes.
研究者
相似试验
尚未招募
不适用
Taking the first step: Investigating the effect of novel strategies on the number of people with knee osteoarthritis accessing exercise management.Knee osteoarthritisMusculoskeletal - OsteoarthritisACTRN12622001414707Kathryn Mills3,060
已完成
不适用
A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study on the effectiveness of cash-based reinforcement therapy on craving in Ecstasy/MDMA users, the mediator role of depressiodepressioncraving of Ecstasy/MDMA use and depressioncash-based reinforcement therapy,craving,Ecstasy/MDMA,TCTR20190628001/A54
招募中
2 期
Immunity boosting effect of Amukkara churanam Siddha drug for the frontliners of COVID health careCTRI/2022/03/041406Ministry of AYUSH
进行中（未招募）
1 期
A STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIAACUTE MYELOID LEUKEMIAEUCTR2017-002822-19-PLPfizer Inc., 235 East 42nd Street, New York, NY 10017729
进行中（未招募）
1 期
A STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIAMedDRA version: 20.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864ACUTE MYELOID LEUKEMIAEUCTR2017-002822-19-FRPfizer Inc., 235 East 42nd Street, New York, NY 10017720